Taking both clinical and experimental data from in vivo and in vitro studies together, ROS mediate the activation of ABL1 to promote cytokine release by triggering NF-κB and STAT3, which may partially account for the poorer prognosis of GC patients with depression. Here, STAT3 is linked to gastric cancer.